Brooklyn ImmunoTherapeutics Total Liabilities

The latest total liabilities for BTX is $24M as of December 2025. That compares with $24M in the prior-year period — down 0.4% year over year. Investors often review this figure alongside Brooklyn ImmunoTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTX's total liabilities moved from $24M to $24M — a 0.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brooklyn ImmunoTherapeutics's operating scale or balance-sheet position.

A total liabilities figure of $24M for BTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BTX's total liabilities ($24M), review year-over-year change from $24M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Brooklyn ImmunoTherapeutics's total liabilities against similar Telecommunications names. You can also browse sector and industry screens on Stockcircle for a broader set of Telecommunications companies and their key multiples and fundamentals.